Dirk Sibbing on Antithrombotic Drugs for ACS in Women
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, reposted from Women As One on LinkedIn:
”Important contribution to the field of tailored treatment in cardiovascular disease…
Gender matters when it comes to antithrombotic treatment in ACS patients”
Qutoing Women As One‘s post:
”Analysis highlights how women with acute coronary syndromes (ACS) experience distinct benefits and risks from antithrombotic therapy, signaling an urgent need for sex-specific treatment strategies.
Published in the European Heart Journal, the paper led by Dr. Valeria Paradies and Jolanta Siller-Matula, explores the current barriers and potential interventions to improve the recruitment of women in cardiovascular trials.
Key Insights:
- Women show different bleeding and thrombotic risk profiles compared to men.
- Standard ACS guidelines, historically based on male-dominant data, may misestimate risks in women.
- The study reinforces the importance of representative clinical trials designed to capture these sex-related nuances.
This study underscores why clinical trials must include adequate numbers of women to uncover critical sex-based treatment effects, and findings should feed into female-specific clinical guidance and decision-making in daily practice.
We need continued advocacy for awareness, funding, and research that reflects real-world diversity.”
Read the full article here.
Article: Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosi
Authors: Valeria Paradies, Giulia Masiero, Andrea Rubboli, Heleen M M Van Beusekom, Francesco Costa, Piera Capranzano, Sophie Degrauwe, Diana A Gorog, Claudia Moreira Jorge, Gill Louise Buchanan, Mirvat Alasnag, Daniela Trabattoni, Chiara Fraccaro, Dirk Sibbing, Dariusz Dudek, Gemma Vilahur, Alaide Chieffo, Roxana Mehran, Davide Capodanno, Emanuele Barbato, Jolanta M Siller-Matula
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:34Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
-
Jul 4, 2026, 15:20Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis